玫瑰红孟加拉光动力抗菌疗法治疗进行性感染性角膜炎:一项初步临床研究
该连续干预性病例系列在Bascom Palmer眼科研究所纳入2016年1月至2018年3月标准药物治疗无效的进行性感染性角膜炎患者18例,接受玫瑰红孟加拉光动力抗菌疗法(RB-PDAT)作为辅助治疗。72%的病例成功避免治疗性角膜移植,平均临床缓解时间46.9±26.4天。作者认为RB-PDAT可考虑作为严重进行性感染性角膜炎在治疗性角膜移植前的辅助疗法。
要点
- RB-PDAT方案:去上皮角膜应用0.1%或0.2%玫瑰红孟加拉溶液30分钟,随后以6 mW/cm2定制绿色LED光源照射15分钟(5.4 J/cm2)。
- 18例患者中棘阿米巴最常见(10/17;59%),其次为镰刀菌属(4/17;24%)、铜绿假单胞菌(2/17;12%)和弯孢菌属(1/17;6%)。
- 72%的病例成功避免治疗性角膜移植,平均临床缓解时间46.9±26.4天,随访13.3±5.7个月。
核心结论
- 作者认为RB-PDAT可考虑作为严重进行性感染性角膜炎在实施治疗性角膜移植前的辅助疗法。
研究设计与样本
- 连续干预性病例系列,纳入2016年1月至2018年3月在Bascom Palmer眼科研究所接受RB-PDAT的进行性感染性角膜炎且标准药物治疗无效的患者18例(男性7例、女性11例,年龄17至83岁)。
主要发现
- 微生物学:棘阿米巴最常见(10/17;59%),其次为镰刀菌属(4/17;24%)、铜绿假单胞菌(2/17;12%)、弯孢菌属(1/17;6%);1例患者无确认的微生物学诊断。
- 角膜炎主要临床危险因素包括佩戴接触镜(79%)。
- 首次RB-PDAT前上皮缺损平均面积32±27 mm2,眼前节光学相干断层扫描测得基质深度高反射平均269±75 μm。
- 成功RB-PDAT(避免治疗性角膜移植)达72%的病例,RB-PDAT后平均临床缓解时间(疼痛和炎症减轻伴再上皮化及浸润消退)为46.9±26.4天,RB-PDAT后随访时间13.3±5.7个月。
关键数值与推荐
- RB-PDAT操作:将玫瑰红孟加拉溶液(0.1%或0.2% RB溶于平衡盐溶液)应用于去上皮角膜30分钟,随后以6 mW/cm2定制绿色LED光源照射15分钟(5.4 J/cm2)。
临床怎么用
- 作者认为RB-PDAT可考虑作为严重进行性感染性角膜炎在治疗性角膜移植前的辅助疗法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report clinical outcomes of rose bengal photodynamic antimicrobial therapy (RB-PDAT) as an adjunct treatment for severe, progressive infectious keratitis. DESIGN: Consecutive interventional case series. METHODS: Patients with progressive infectious keratitis unresponsive to standard medical therapy underwent RB-PDAT at the Bascom Palmer Eye Institute from January 2016 through March 2018. RB-PDAT was performed by applying a solution of rose bengal (0.1% or 0.2% RB in balanced salt solution) to the de-epithelialized cornea for 30 minutes, followed by irradiation with a 6 mW/cm2 custom-made green LED source for 15 minutes (5.4 J/cm2). RESULTS: The current study included 18 patients (7 male and 11 female) ranging from 17 to 83 years old. Acanthamoeba was the most frequent microbe (10/17; 59%), followed by Fusarium spp. (4/17; 24%), Pseudomonas aeruginosa (2/17; 12%), and Curvularia spp. (1/17; 6%); 1 patient had no confirmed microbiologic diagnosis. Main clinical risk factor for keratitis included contact lens wear (79%). The average area of epithelial defect prior to first RB-PDAT was 32 ± 27 mm2 and average stromal depth hyperreflectivity measured with anterior segment optical coherence tomography was 269 ± 75 μm. Successful RB-PDAT (avoidance of therapeutic keratoplasty) was achieved in 72% of the cases, with an average time to clinical resolution (decreased pain and inflammation with re-epithelialization and infiltrate resolution) of 46.9 ± 26.4 days after RB-PDAT. Time of follow-up after RB-PDAT was 13.3 ± 5.7 months. CONCLUSION: RB-PDAT can be considered as an adjunct therapy for cases of severe, progressive infectious keratitis before performing a therapeutic keratoplasty.
引用
- Naranjo A, Arboleda A, Martinez JD, et al. Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis: A Pilot Clinical Study. Am J Ophthalmol. 2019. PMID: 31493402. doi:10.1016/j.ajo.2019.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。